NCT00227019 - Phase 2 Trial of Bevacizumab in Combination With Pemetrexed | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2010

Study Completion Date

December 31, 2016

Conditions

Non-small Cell Lung Cancer (NSCLC)Lung CancerNeoplasm Metastasis

Interventions

DRUG

Bevacizumab

15 mg/kg, IV over 10 minutes every 3 weeks

DRUG

Pemetrexed

500 mg/m²; IV over 10 minutes every 3 weeks

DRUG

Vitamin B12

1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed

DRUG

Folate

350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose

DRUG

Dexamethasone

4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed

Trial Locations (4)

University of North Carolina, Chapel Hill

Stanford University School of Medicine, Stanford

Norris Cotton Cancer Center, Lebanon

Cooper Cancer Institute, Voorhees Township